Development of targeted therapies for Parkinson's disease and related synucleinopathies
Therapeutic efforts in neurodegenerative diseases have been very challenging, particularly due to a lack of validated and mechanism-based therapeutic targets and biomarkers. The basic idea underlying the novel therapeutic approaches reviewed here is that by exploring the molecular basis of neurodege...
Main Authors: | Edmund Sybertz, Dimitri Krainc |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-10-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520350033 |
Similar Items
-
Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
by: Mylene Huebecker, et al.
Published: (2019-11-01) -
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy
by: Mali Cosden, et al.
Published: (2021-11-01) -
Impaired β-glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations
by: Andrew E. Arrant, et al.
Published: (2019-12-01) -
The Emerging Role of the Lysosome in Parkinson’s Disease
by: Alba Navarro-Romero, et al.
Published: (2020-11-01) -
Glucocerebrosidase involvement in Parkinson Disease and other Synucleinopathies
by: Maria Rosario Almeida
Published: (2012-04-01)